^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

U2AF1 S34F

i
Other names: U2AF1, U2 Small Nuclear RNA Auxiliary Factor 1, U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein, U2 SnRNP Auxiliary Factor Small Subunit, Splicing Factor U2AF 35 KDa Subunit, U2AFBP, U2AF35, U2 Small Nuclear Ribonucleoprotein Auxillary Factor, 35-KD Subunit, U2(RNU2) Small Nuclear RNA Auxiliary Factor 1, U2 Small Nuclear RNA Auxillary Factor 1, Splicing Factor U2AF 35kDa Subunit, U2 Auxiliary Factor 35 KDa Subunit, RNU2AF1, FP793, RN
Entrez ID:
Related biomarkers:
1year
U2AF1 S34F enhances tumorigenic potential of lung cells by exhibiting synergy with KRAS mutation and altering response to environmental stress. (PubMed, bioRxiv)
Interestingly, HBEC3kts harboring only U2AF1 S34F display increased splicing in stress granule protein genes and viability in cigarette smoke concentrate. Our results suggest that U2AF1 S34F may potentiate transformation by granting precancerous cells survival advantage in environmental stress, permitting accumulation of additional mutations like KRAS G12V , which synergize with U2AF1 S34F to transform the cell.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
|
KRAS mutation • KRAS G12V • KRAS G12 • U2AF1 mutation • U2AF1 S34F
almost2years
Mutant U2AF1-induced mis-splicing of mRNA translation genes confers resistance to chemotherapy in acute myeloid leukemia. (PubMed, Cancer Res)
A pharmacologic inhibitor of ISR, ISRIB, sensitized U2AF1 mutant cells to chemotherapy. These findings highlight a resistance mechanism by which U2AF1 mutations drive chemoresistance and provide a therapeutic approach for AML through targeting the ISR pathway.
Journal
|
U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
|
U2AF1 mutation • U2AF1 S34F
almost2years
Primary myelofibrosis with double mutation in U2AF1 (PubMed, Rinsho Ketsueki)
Although U2AF1 gene abnormality is known as a poor prognostic factor in primary myelofibrosis, this patient had a favorable long-term prognosis due to prompt transplantation therapy. This case highlights the importance of detailed gene mutation analysis in patients with triple-negative MF.
Journal
|
JAK2 (Janus kinase 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CALR (Calreticulin)
|
U2AF1 mutation • U2AF1 S34F
almost2years
Genetic Characteristics of Patients with Young-Onset Myelodysplastic Neoplasms. (PubMed, J Clin Med)
In conclusion, a germline predisposition to myeloid neoplasms occurred in ~16% of young-onset MDS patients and was largely associated with primary immunodeficiencies, including GATA2 deficiency. Furthermore, the high frequency of somatic U2AF1 mutations in patients with young-onset MDS suggests the presence of a distinct MDS subtype.
Journal
|
U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
|
U2AF1 mutation • U2AF1 S34F
2years
Small-Molecule U2 Auxiliary Factor Homology Motif (UHM) Domain Inhibitors Cause Splicing Pattern Changes in U2AF1 Mutant Leukemia Cells and Induce Sub-G1 Cell Cycle Arrest (ASH 2023)
In summary, SF-1-8 caused disruption of extra- and intracellular protein transport in K562-U2AF1S34F cells and represented a new class of small-molecule inhibitors to target U2AF1-UHM. Further optimization of this class of compounds will allow us to develop effective chemical probes for study in the U2af1 murine models and assess the potential of U2AF1 as a therapeutic target in MDS and sAML.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • SF3B1 (Splicing Factor 3b Subunit 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • ASAP1 (ArfGAP With SH3 Domain) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2) • ATF3 (Activating Transcription Factor 3)
|
U2AF1 mutation • U2AF1 S34F